People started sharpening their focus on glucocorticoids in the middle of the twentieth century. Research teams saw anti-inflammatory steroid molecules as a ticket to better medicine for asthma, allergies, and joint pain. Betamethasone’s roots trace back to early breakthroughs with cortisone and hydrocortisone, where chemists discovered that tweaking certain positions on the steroid core could make the molecules more potent and longer-lasting. By the 1960s, betamethasone intermediates became cornerstones in multistep organic synthesis. Scientists realized that modifying androgens and corticosteroids took patience and clever chemistry. Even with advances in green chemistry and automation, the fundamental reactions rely on foundational research led by pioneers in pharmaceutical labs over half a century ago. These early steps laid groundwork that continues to shape how companies and researchers approach corticosteroid synthesis today.
At its core, a betamethasone intermediate acts as a building block in the production chain leading up to the final, medically active steroid. These molecules rarely end up in pharmacies or hospitals; instead, they fuel the chemical transformations that ultimately create familiar topical creams, injectables, and inhalers. For chemists, each intermediate carries crucial features: a steroid skeleton, key functional groups ready for further transformation, and, most importantly, high purity. Any impurities can derail the synthesis, waste raw materials, and jeopardize the quality of the final drug. In my work with pharmaceutical manufacturers, oversight on intermediate quality often invites costly recalls and regulatory headaches.
Betamethasone intermediates typically present as white to off-white crystals or fine powders. Molecular weights sit in the 350–400 range for most common derivatives. They dissolve well in organic solvents like dichloromethane and ethyl acetate, while resisting water absorption. Their melting points often reveal information about proper storage: intermediate breakdown may begin above 200°C, so cool, dry, airtight conditions matter on the lab and production floors. Chemically, these molecules stand on a cyclopentanoperhydrophenanthrene core—steroid language for a fused ring system. What sets betamethasone-related intermediates apart are subtle substitutions: halogenation at certain rings, or hydroxylation at carbon-17, each decision shaping reactivity and final biological impact.
Buyers and users look for batch-specific certificates of analysis, listing purity typically above 98%, and clear identification by spectral analysis like NMR and IR, sometimes supported by mass spectrometry. Labeling reflects compliance with local and global regulations—think IUPAC names, lot numbers, expiration dates, and hazard warnings based on the latest chemical safety databases. Laboratories often require documentation on storage stability, with steadfast attention to hazardous decomposition warnings as these compounds end up exposed to acids, bases, and heat in multi-step synthesis. The best-run chemical facilities keep all paperwork up to date, not just because regulators demand it but because small missteps in labeling and handling have ripple effects throughout a tightly regulated supply chain.
Synthesizing betamethasone intermediates requires a controlled sequence of reactions, most of them rooted in years of organic chemistry know-how. Common routes begin with a base corticosteroid, such as hydrocortisone or prednisolone, which then undergoes reactions like selective oxidation, acetylation, or halogenation. Catalysts and protecting groups guide these changes, isolating the desired product after each step using extraction and crystallization. Some routes depend on enzyme-catalyzed transformation, which can boost yields and reduce toxic byproducts. From my perspective, process chemists pay close attention to yield optimization and waste management—both deliver cost savings and regulatory peace of mind. Facing supply chain kinks and batch variability, many manufacturers adopted continuous flow synthesis, which improves scalability and reduces downtime.
Reactivity defines how intermediates slot into the overall build-up to betamethasone. The introduction of methyl and fluorine groups on specific positions changes the molecule’s shape and charge, amplifying its anti-inflammatory punch in the final formulation. Another key modification is hydroxylation at C-17, which enables later esterification steps. In practice, reaction yields and side-product formation shape both cost and feasibility. Many researchers push for greener routes, swapping toxic reagents for safer ones, or deploying biocatalysts instead of heavy metals. Downstream pharmaceutical quality checkpoints tie back to these core reactions—scrutinizing the intermediates for leftover solvents, unconverted starting material, or unexpected byproducts.
People in the field know these intermediates by a mix of systematic chemical names and trade names. For example, 9α-Fluoro-16β-methylprednisolone is one well-used betamethasone intermediate, and many suppliers market it under catalog descriptions such as Betamethasone precursor, Betamethasone base intermediate, and variant-specific identifiers tied to particular reaction steps. It’s common for labs and manufacturers to use shorthand codes to systematize ordering and inventory management, especially when juggling similar corticosteroid intermediates. In catalogs, CAS numbers remain king, ensuring buyers and regulators match the right substance to the right use.
Working with betamethasone intermediates means taking chemical safety seriously. Inhalation or contact risks lurk, particularly for powders with high biological activity. Long shifts in synthesis or packaging rooms can lead to accidental exposure if engineering controls and PPE slip. I’ve seen companies introduce double-glove protocols, mandatory fume hoods, and exhaustive safety training to keep workers healthy. Regulatory guides like the Globally Harmonized System of Classification and Labelling of Chemicals (GHS) requires clear pictograms and emergency response procedures. For bulk storage and shipping, companies invest in secondary containment and leak-proof containers, since a single spill can prompt expensive clean-up and interrupted production schedules. Safety and quality always walk hand-in-hand in complex pharmaceutical syntheses.
Betamethasone intermediates serve as linchpins in the drug manufacturing pipeline. Their main job lies in helping chemists build the potent corticosteroids used for severe inflammation, autoimmune flare-ups, allergic reactions, and niche disorders such as Addison’s disease. These intermediates contribute to topical ointments, oral tablets, and long-acting depot formulations that doctors count on in clinics and hospitals. Some intermediates also feed into veterinary medicine supplies, broadening access to anti-inflammatory treatments for livestock and companion animals. As regulatory agencies press for greater consistency and transparency, these intermediates turn into crucial checkpoints in global pharmaceutical traceability systems.
R&D on betamethasone intermediates never stands still. Teams across industry and academia look for ways to improve synthetic efficiency, cut down on hazardous byproducts, and stretch the shelf stability of intermediates shuttled through international supply chains. New catalysts drive selectivity up and waste down. In some circles, scientists engineer enzyme variants or leverage computational modeling to speed up reaction discovery. These shifts lower material costs and improve regulatory compliance, since continuous process updates must track with environmental and worker-safety rules. A push for sustainable manufacturing also means more scientists re-examine solvent choices and purification methods, intent on reducing the overall carbon footprint.
From the earliest days making corticosteroid intermediates, chemists recognized that unintended exposure could harm lab workers and eventually, the environment. Toxicologists continue to screen new intermediates for acute and chronic effects, relying on animal studies and computational modeling to predict skin, eye, and inhalation risks. For the most potent intermediates, trace contamination in manufacturing plants prompts strict air and surface monitoring. Waste handling procedures limit environmental impact, with careful solvent recovery and disposal of biologically active residues. Regulatory reviews draw on these studies to set occupational exposure limits and inform emergency response planning.
The horizon for betamethasone intermediate production keeps widening. Expanding demand for affordable anti-inflammatory treatments across low- and middle-income countries spurs both established firms and new entrants to refine and scale up intermediate production. Advanced chemistry methods cut down on waste, energy use, and hazardous reagents, standing as both risk reducers and bottom-line boosters. Governments increasingly back public-private research partnerships aimed at developing faster, cleaner routes for corticosteroid intermediates, powering both economic growth and better health outcomes. As digital tools enter chemical manufacturing—tracking batches in real time, automating quality checks—companies can both improve worker safety and reduce the risk of defective lots reaching medicine cabinets around the globe.
Betamethasone intermediate plays a quiet but crucial part in the world of medicine. While the name might sound technical or distant, its impact is anything but abstract. As someone who’s spent years speaking with pharmacists and doctors, I’ve noticed how often we overlook the steps before a finished drug lands on the pharmacy shelves. This intermediate is one of those steps—a chemical milestone vital for making betamethasone, a steroid that’s been easing pain and inflammation for generations.
People living with allergies, eczema, and asthma probably know betamethasone well, even if by a brand name. Its ability to calm angry rashes or swollen joints isn’t accidental. The journey starts with these intermediates, handled by skilled chemists who make sure each batch contains the right purity and strength. That level of care shows why betamethasone intermediate demands respect. The stakes are high: a misstep in this early process could affect everyone waiting for relief from steroids, whether as pills, creams, or injectables.
The way these intermediates get produced matters for every patient. In my conversations with regulatory specialists, the fear of substandard or counterfeit ingredients comes up time and again. Cutting corners, even at the earliest stage, leads to weak or inconsistent drugs. Regulatory agencies like the FDA and EMA set strict rules for manufacturing and tracking intermediates. They require batch records, supplier audits, and chemical analysis at every turn. It’s not overkill—it’s what keeps patients safe from impurity-driven side effects and treatment failures.
Major pharmaceutical manufacturers rely on intermediates to scale up production. Smaller producers sometimes source them globally, seeking lower costs, but that has introduced challenges. Supply chain disruptions, especially over the past few years, have made it harder to get quality intermediates on time. Some countries have responded by investing in local production and tightening customs checks to block suspicious shipments.
Healthcare providers, especially those in dermatology and rheumatology, depend on reliable supplies. Without these upstream chemicals, options dwindle for treating autoimmune flares, severe allergies, or certain skin problems. As a patient or family member, you might not see the lab coats working with betamethasone intermediates, but their vigilance trickles down to every pharmacy counter.
Many current issues touch the world of intermediates: environmental impact from chemical manufacturing, workforce shortages, and keeping up with stricter global rules. Some companies have started investing in greener chemical processes, using less toxic solvents or recycling byproducts to cut waste. Others partner with governments and universities to train new chemists and technicians. Greater transparency, with digital traceability from origin to finished dose, has helped catch problems earlier, before a low-quality batch moves down the line.
Improved global coordination stands as the clearest way to protect patients. Greater communication between regulators and more frequent inspections mean fewer weak links in the long chain from raw material to prescription. For anyone who relies on betamethasone, the safety and consistency at the intermediate stage remain just as important as what’s printed on the medicine box.
A lot of folks overlook what happens to chemicals before they reach the production floor. Betamethasone intermediate—a key raw material for corticosteroid medicines—demands a bit of respect right from the warehouse. Humidity, light, and temperature shifts may chip away at the quality of the intermediate, reshaping what was once a powerful starting block into a liability. The anecdotes I’ve heard from colleagues and my own stints in pharmaceutical handling keep repeating the same theme: the success of the end medicine tracks right back to the care taken at the storage stage.
Most manufacturers recommend keeping betamethasone intermediate under 25°C, out of direct sunlight, and well away from heat sources. There’s always pressure to cut costs on utilities, but putting a few pallets in a warm back room almost guarantees trouble. From what I’ve seen in mid-sized facilities, staff struggles with inconsistent HVAC systems, especially in older warehouses. Those temperature spikes in summer get into the powder. Over time, this can trigger slow chemical changes or clumping. One ruined batch means headaches for every downstream process—blending, tableting, packaging, insurance claims, and, worst of all, patient safety.
Moisture creeps in more easily than most expect. Betamethasone intermediate pulls in water if it can. Humidity control isn’t just a checklist item—it’s an ongoing fight. I’ve watched teams use simple silica gel packs all the way up to industrial-grade dehumidifiers. The smallest leak around doors or a missing gasket in the HVAC becomes a slow disaster. Once moisture gets in, caking and microbial growth follow. Losing a container or two gets expensive—and if that batch ships out and doesn’t get caught in testing, quality control headaches spiral out. There’s no shortcut here: keep things sealed, keep air dry, and staff should check meters, not just trust digital readings from afar.
Contamination rarely announces itself. Only one open lid, a single dusty forklift, or a tardy janitor can throw up issues that no one sees until the final product. Strict “first-in, first-out” rotation helps, and I’ve found keeping a dedicated clean space gives staff fewer mixed messages. Some try to save space by mixing actives with other chemicals in the same bay—more times than I like, faulty seals, cross-contamination, or simple mislabeling follow.
Paper protocols may look fine to inspectors, but the real world is much messier. Regular walk-throughs matter more than isolated audits. Staff who understand the reasons behind separate storage areas, clear labeling, and temperature/humidity logs are far less likely to cut corners. Open conversations between warehouse and quality control guarantee fewer surprises. Investing in easy-to-read data loggers, training refreshers, and frequent unannounced checks builds the right habits. Mistakes get fixed early, not after a disaster.
Those little steps in the warehouse build trust across the chain—manufacturers, regulators, doctors, and patients. Betamethasone intermediate won’t turn into a safe, potent medicine unless it survives the journey intact. If storage slips, the science stumbles. The stakes stay high because patients expect dependable medicine every time, and the only way to deliver is to treat the intermediate with care long before the pill bottle gets filled.
Betamethasone intermediate plays a big part in the pharmaceutical industry. This chemical precursor forms the backbone for producing betamethasone and its derivatives—a group of corticosteroids that help patients struggling with inflammation, allergies, or certain autoimmune conditions. As a writer with years of experience reporting on pharmaceutical topics, I’ve seen few ingredients that stir up as much debate among quality control managers and production supervisors.
Production teams usually worry about the consistency and purity of any ingredient entering a synthesis process. Betamethasone intermediate needs high purity. Even the smallest trace of unknown contaminants can set off a cascade of quality control failures and threaten patient safety. Professional standards, such as those dictated by the United States Pharmacopeia (USP) and European Pharmacopoeia (Ph. Eur.), do not accept much wiggle room here. Products made using low-grade intermediates simply do not make it past good manufacturing practices (GMP) checks.
From my time visiting facilities, it’s clear that only suppliers with a strong track record and robust documentation find a welcoming audience. I recall a plant manager in Shanghai showing visitors binder-thick records for every batch of betamethasone intermediate received—proving stability, purity, and traceability with chemical certificates of analysis and origin. Without that paper trail, pharmaceutical companies risk recalls, regulatory fines, or worse, patient harm.
Quality doesn’t stop at purchase. Betamethasone intermediates react and degrade if handled without proper care. Temperature swings in transport trucks or humidity creeping into a warehouse can quickly change the chemical profile—ruining the batch and pushing up costs, sometimes to disastrous levels. Production chemists and line workers face pressure to control storage conditions and avoid unnecessary delays once a drum lands on the manufacturing floor.
When things go wrong, insurance isn’t enough to mend trust. I once covered a story about a midsize pharma company that had to track down every batch of cream sold after an intermediate failed quality checks due to poor storage. That story came up years later as a cautionary tale during staff training—underlining the stakes at play.
Some overlook the ripple effects of poor intermediate quality. If a pharmaceutical company delivers a drug with too many impurities, doctors lose confidence and patients start questioning prescriptions. On the environmental side, mishandled intermediates sometimes spill or get disposed of in unsafe ways, risking chemical leaks into water or soil. In the long term, responsible sourcing and rigorous waste controls work out better for everyone—from communities near production sites to patients relying on safe, stable medicines.
Factories improve outcomes by building better supplier relationships and investing in analytical testing equipment, not just for the final product but right from the point the intermediate arrives. Training staff to understand early warning signs—off-color material, different smell—helps catch problems before they scatter across the supply chain. Research and sharing experiences at industry conferences do as much as regulation to upgrade habits and practice.
Betamethasone intermediates matter. Their suitability rides on strict attention to sourcing, handling, and a deep respect for the link between raw material and patient outcome.
Anyone who’s worked with chemicals for a while recognizes the confusion that comes from long, similar-sounding names. That’s where a CAS number steps in. If you look at any warehouse or even a well-run pharmacy storeroom, you’ll spot stacks of labels with these unique numbers. These are more than just bureaucratic codes—they give every chemical, no matter how complex or obscure, a clear identity. Regular communication between manufacturers, regulators, and labs would be much trickier without this kind of standardization. With pharmaceuticals, where mistakes can cost time, money, and even lives, clarity really matters.
Betamethasone, a trusted corticosteroid, doesn’t simply appear on store shelves or in hospitals. It comes about through a chain of careful synthesis steps, using a handful of intermediary chemicals. These intermediates might never end up as final products themselves, but their purity and traceability affect every vial or tablet that reaches patients. Factories producing Betamethasone must keep detailed records about every batch of intermediates that pass through their doors. That’s the sort of information that comes up during audits, recalls, and patent disputes.
The CAS number assigned to Betamethasone itself stands as 378-44-9. This points directly to the steroid compound doctors prescribe and pharmacists dispense. Things get murky, though, with “Betamethasone intermediates.” There’s no single intermediate; producers use a range of them as stepping stones in synthesis. Some well-documented intermediates include compounds like Betamethasone 17-valerate, carrying the CAS number 2152-44-5, and Betamethasone 21-acetate, with CAS number 987-24-6. Each manufacturer may focus on different ones, depending on their process.
Let’s say a research lab receives a drum marked “Betamethasone intermediate.” Without a CAS number, the lab staff might guess, but guessing doesn’t cut it when regulations and safety checks come into play. Incorrect intermediates in formulation lead to wasted resources or even regulatory penalties. For major drugmakers and their partners, these records are as important as the machinery itself. Routine use of CAS numbers closes the gap between raw data and safe, reliable medicine.
One fix that works well: require every supplier to label both chemical names and CAS numbers on invoices and containers. This keeps everybody honest and reduces mix-ups. Digital inventory systems now allow technicians to scan barcodes connected to up-to-date chemical registries, putting the right info at everyone’s fingertips. Third-party verification, through audits or independent lab analysis, offers an extra layer of security, especially when compounds arrive from overseas or unfamiliar sources.
As regulatory checks keep getting tighter, there’s little room for ambiguity about chemical identity. Anyone serious about producing Betamethasone intermediates has to track CAS numbers just as carefully as batch numbers or expiration dates. Students, lab workers, and procurement teams learn to check these numbers early and often. With so much riding on precision, CAS numbers turn into more than mere codes; they’re lifelines for everyone working behind the scenes in pharmaceutical science.
Betamethasone intermediate doesn’t show up in everyday headlines, but anyone who spends time in chemical labs knows its reputation. At first look, you’re dealing with a white or off-white solid, nothing flashy. Still, what’s under the surface gives reason for pause. This substance forms a bridge in making potent corticosteroids, which means it can pack a punch if it lands where it doesn’t belong—like on your skin or in your lungs.
Back in the days of stacked glassware and chalkboards, even my earliest mentors stressed no shortcuts with intermediates. I’ve seen rashes and coughing fits from those who got careless. Dust on clothes, chemical splashes—small mistakes, big reminders. Making sure hazards stay controlled isn’t just for regulatory reports, it’s about getting everyone home with the same number of fingers and toes.
The strictest mask in the world won’t matter if gloves get ignored. I trust snug-fitting nitrile gloves every time I measure or transfer this compound. Double-checking for pinhole tears beats swapping out more irritated hands. The feeling of powder on skin will haunt you for days if safety takes a back seat for only a minute.
Moving to the eyes, even a slight dust in the air can spell stinging or much worse. Goggles that seal well around the face make all the difference, especially on busy benches where distractions pop up. I’ve used splash shields as added security during bigger transfers, and that sense of relief when nothing goes flying is well worth the awkward reach.
The stuff never leaves my bench without the fume hood whirring. Airflow isn’t about feeling cool, it’s about keeping invisible particles from taking the fast track to my lungs. Some colleagues tease about overdoing the sash height, but a bit of paranoia beats a wheezing afternoon. I’ve met workers in pharma plants who saw long-term lung damage from getting cavalier. Listening to their stories etched the importance of good ventilation in my mind for good.
Newcomers sometimes roll their eyes at the extra steps, but one splatter accident changes minds in a hurry. Showing safe habits, not just rattling off rules, keeps those around me alert. I always clean the workspace before and after, keeping spills from turning into slow-building hazards. The small effort pays off every time someone avoids a ruined lab notebook or, worse, a trip to the clinic. Responsibility runs deeper when others look to you as an example.
People tend to focus on what goes wrong at the bench, yet the aftermath creates just as many traps. I keep tightly sealed containers for every bit of intermediate waste, never mixing it with general solvents. Clearly labeled bags and bins stay locked away from work surfaces and food. In shared spaces, clear signposting prevents a mix-up that could endanger the next shift. Watching a mentor lose her lunch to an unlabeled pot left by someone else always stuck with me—details prevent bigger headaches.
Safety talks sometimes feel dry, but they keep the real dangers at bay. It’s more than just patches on a lab coat; every step protects people and keeps the whole operation running. The core lesson: never trust a familiar routine to stay safe on its own. With each transfer, each cleanup, that steady attention to detail preserves both health and hard-earned trust. That’s what grounds a truly responsible lab—one careful step at a time.
| Names | |
| Preferred IUPAC name | (11β,16β)-9-fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione |
| Other names |
Betamethasone 16β,17α-Dihydroxy-9α-fluoro-11β,21-dioxopregna-1,4-diene-3,20-dione
S-(+)-Betamethasone Intermediate Betamethasone Base Intermediate |
| Pronunciation | /ˌbiː.təˈmeθ.ə.səʊn ˌɪn.təˈmiː.di.ət/ |
| Preferred IUPAC name | (11β,16β)-9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione |
| Other names |
Betamethasone 16α,17α-acetonide
Betamethasone 16,17-acetonide Betamethasone acetate intermediate 9α-Fluoro-16β-methylprednisolone |
| Pronunciation | /ˌbiː.təˌmiː.θəˈsoʊn ˌɪn.tərˈmiː.di.ət/ |
| Identifiers | |
| CAS Number | 2152-44-5 |
| Beilstein Reference | 3950816 |
| ChEBI | CHEBI:15374 |
| ChEMBL | CHEMBL1200723 |
| ChemSpider | 50900710 |
| DrugBank | DB00443 |
| ECHA InfoCard | 03ca1a16-b769-430a-a61a-afb9f398a422 |
| EC Number | 248-725-7 |
| Gmelin Reference | 86938 |
| KEGG | C16000 |
| MeSH | D002045 |
| PubChem CID | 124336 |
| RTECS number | JZ9265000 |
| UNII | 1U1QTN40SY |
| UN number | UN2811 |
| CompTox Dashboard (EPA) | DTXSID10898398 |
| CAS Number | 434-16-2 |
| Beilstein Reference | 3939352 |
| ChEBI | CHEBI:3075 |
| ChEMBL | CHEMBL1200675 |
| ChemSpider | 27846142 |
| DrugBank | DB00443 |
| ECHA InfoCard | echa.europe.eu/information-on-chemicals/infocards/100.266.336 |
| EC Number | 2916399000 |
| Gmelin Reference | 71534 |
| KEGG | C16473 |
| MeSH | D002031 |
| PubChem CID | 11954214 |
| RTECS number | JN7070000 |
| UNII | 441YNJ6UHN |
| UN number | UN2811 |
| Properties | |
| Chemical formula | C22H29FO5 |
| Molar mass | 392.47 g/mol |
| Appearance | White or almost white crystalline powder |
| Odor | Odorless |
| Density | 1.2 g/cm³ |
| Solubility in water | Sparingly soluble |
| log P | 1.92 |
| Acidity (pKa) | 12.59 |
| Basicity (pKb) | 12.53 |
| Refractive index (nD) | 1.514 |
| Dipole moment | 2.79 D |
| Chemical formula | C22H29FO5 |
| Molar mass | 392.46 g/mol |
| Appearance | White or almost white crystalline powder |
| Odor | Odorless |
| Density | 1.34 g/cm³ |
| Solubility in water | Insoluble in water |
| log P | 1.92 |
| Acidity (pKa) | 12.59 |
| Basicity (pKb) | 8.83 |
| Refractive index (nD) | 1.5400 |
| Dipole moment | 2.79 D |
| Thermochemistry | |
| Std enthalpy of formation (ΔfH⦵298) | -795.2 kJ/mol |
| Std molar entropy (S⦵298) | Std molar entropy (S⦵298) of Betamethasone Intermediate is 576.4 J·mol⁻¹·K⁻¹ |
| Pharmacology | |
| ATC code | H02AB01 |
| ATC code | H02AB01 |
| Hazards | |
| Main hazards | May cause respiratory irritation. |
| GHS labelling | GHS05, GHS07 |
| Pictograms | GHS05,GHS07 |
| Signal word | Warning |
| Hazard statements | H315: Causes skin irritation. H319: Causes serious eye irritation. H335: May cause respiratory irritation. |
| Precautionary statements | P264, P280, P305+P351+P338, P337+P313 |
| NFPA 704 (fire diamond) | 1-1-0 |
| Flash point | Flash point: 181.6°C |
| Lethal dose or concentration | Lethal dose or concentration: "LD50 (oral, rat): >3,000 mg/kg |
| LD50 (median dose) | 1750 mg/kg (Rat, Oral) |
| NIOSH | SN4300000 |
| REL (Recommended) | 0.01% |
| Main hazards | May cause eye, skin, and respiratory tract irritation. |
| GHS labelling | GHS05, GHS07 |
| Pictograms | GHS07, GHS08 |
| Signal word | Warning |
| Hazard statements | H315, H319, H335 |
| Precautionary statements | Keep container tightly closed. Keep container in a cool, well-ventilated place. Avoid breathing dust, vapor, mist or gas. Avoid contact with skin and eyes. Wash thoroughly after handling. Use personal protective equipment as required. |
| Flash point | Flash point: 291.8°C |
| LD50 (median dose) | Betamethasone 477 mg/kg (rat, oral) |
| PEL (Permissible) | 1.0 mg/m3 |
| REL (Recommended) | Not for human use |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
Betamethasone
Betamethasone valerate Betamethasone dipropionate Dexamethasone Hydrocortisone Prednisolone Triamcinolone Fluticasone |
| Related compounds |
Betamethasone
Betamethasone valerate Betamethasone dipropionate Dexamethasone Prednisolone Hydrocortisone |
Providing high-quality chemical products and logistics solutions for global trade partners.
